Plan & implement

Consultancy

Scientific and technical guidance for pharmaceutical, research and healthcare teams.

Discuss Your Requirements

Discuss Your Requirements

Explore

Three consultancy areas

One practice, three ways we can help.

Choose the area closest to your project. Each one shows what we help with, what you bring, what you receive and a sample engagement.

01

Pharmaceutical Consultancy

Strategy and evidence for pharmaceutical and biotechnology projects.

02

AI in Healthcare Implementation

Plan, introduce and evaluate AI within healthcare workflows.

03

Scientific & Bioinformatics Consultancy

Research design, methods and interpretation.

Pharmaceutical consultancy

Strategy that starts from the evidence.

Where the question is strategic as well as scientific, we help you set priorities, review the evidence, plan biomarker and target work and scope the computational research that supports it.

Pharmaceutical teams

Biotechnology companies

Translational research groups

Questions we help with

01

Which research directions deserve priority, and what evidence supports them?

02

What does the existing evidence show, and where are the gaps?

03

Which biomarkers or targets are worth taking forward, and how should they be validated?

04

What data, methods and resources does the computational plan need?

Where we can help

01

Drug Discovery Strategy

Define research priorities and evidence needs.

02

Translational Research Planning

Connect molecular research objectives with translational questions.

03

Biomarker Strategy

Plan discovery, prioritisation and validation.

04

Scientific Evidence Review

Assess available evidence and its limitations.

05

Computational Research Planning

Scope methods, data and technical requirements.

Your starting point

Research objectives, available data, current challenges and intended outcomes.

Agreed deliverables

An evidence review, recommendations, a strategy or an implementation plan.

Sample engagement

Follow a sample engagement from strategy to plan.

Click through the tabs. Illustrative sample data, no client information.

StrategyEvidenceTranslatePlanprogramme scoping · illustrative5research questions12candidate aims3priorities4evidence gapsPRIORITY RANKINGrelative valueAim A9Aim B7.6Aim C6.4Aim D4.8Aim E3.5ranked against agreed criteriaFROM QUESTIONS TO A PLANnarrowingOpen questions12Candidate aims8Priorities3Agreed plan1scope agreed with your teamAIM × EVIDENCE TYPEwhat is neededLit.OmicsClin.AssayAim AAim BAim CAim DAim Ewhere evidence is thinPROGRAMME FOCUSshare of effortTarget biology32%Biomarkers28%Translational22%Computational18%balanced across themesROADMAPphasesScopecompleteReviewin progressPlanplannedDecideplannedQUESTIONS AGREEDchecksObjectives definedSuccess criteria setConstraints notedData sources listed420records screened38studies included5evidence themes3gaps foundEVIDENCE SCREENING420 → 38Records screened420Relevant120Eligible64Included38inclusion criteria appliedEVIDENCE BY THEMEstudiesTheme 114Theme 210Theme 37Theme 45Theme 52where the evidence sitsEFFECT ACROSS STUDIES95% CIStudy 1Study 2Study 3Study 4Pooledeffect size (95% CI)direction agrees, precision variesTHEME × STUDY TYPEcoverageRCTCohortOmicsIn vitroscoreT188%T274%T363%T451%T538%strongest where several types agreeSTUDY QUALITYscorequality scorequality weighed, not hiddenLIMITATIONS NOTEDchecksSmall samples flaggedHeterogeneity reviewedPublication bias consideredMissing data stated24candidate markers6shortlisted3assay routes2endpointsCANDIDATE DISCOVERYdifferentiallog₂ fold change−log₁₀ pcandidates pass effect and significanceSHORTLISTING24 → 6Candidates24Robust14Plausible9Shortlist6stepwise, with reasons recordedMARKER × PLATFORMfeasibilityArrayPCRImmunoMSM1M2M3M4M5routes to a practical assayDISCRIMINATIONROCShortlist0.84Best single0.721 − specificityshortlist beats any single markerPATHWAY CONTEXTnetworkTargetPathwayMarkerOutcomemarkers tied to biologyMARKER RANKINGtop 6Marker 19.1Marker 28Marker 37.1Marker 45.8Marker 54.9Marker 63.8evidence-weighted score11weeks4work packages6data needs1planWORK PLANpackagesDesigncompleteDatain progressAnalysisplannedReviewplannedReportplannedEFFORT BY PACKAGEweeksAnalysis5Data3Review2Design1eleven weeks in totalDATA AND COMPUTE NEEDSchecksCohort access confirmedCompute plan setMethods agreedClinical metadataRESOURCE SPLITshareScientific lead34%Analyst38%Your team28%clear ownersRISKSlikelihood × impactLowMedHighDataMethodTimelineScopetracked and mitigatedDELIVERABLEShandoverEvidence reviewRecommendationsStrategy documentImplementation planillustrative sample engagement, no client data

01

Pharmaceutical Consultancy

Strategy and evidence for pharmaceutical and biotechnology projects.

02

AI in Healthcare Implementation

Plan, introduce and evaluate AI within healthcare workflows.

03

Scientific & Bioinformatics Consultancy

Research design, methods and interpretation.

Pharmaceutical consultancy

Strategy that starts from the evidence.

Where the question is strategic as well as scientific, we help you set priorities, review the evidence, plan biomarker and target work and scope the computational research that supports it.

Pharmaceutical teams

Biotechnology companies

Translational research groups

Questions we help with

01

Which research directions deserve priority, and what evidence supports them?

02

What does the existing evidence show, and where are the gaps?

03

Which biomarkers or targets are worth taking forward, and how should they be validated?

04

What data, methods and resources does the computational plan need?

Where we can help

01

Drug Discovery Strategy

Define research priorities and evidence needs.

02

Translational Research Planning

Connect molecular research objectives with translational questions.

03

Biomarker Strategy

Plan discovery, prioritisation and validation.

04

Scientific Evidence Review

Assess available evidence and its limitations.

05

Computational Research Planning

Scope methods, data and technical requirements.

Your starting point

Research objectives, available data, current challenges and intended outcomes.

Agreed deliverables

An evidence review, recommendations, a strategy or an implementation plan.

Sample engagement

Follow a sample engagement from strategy to plan.

Click through the tabs. Illustrative sample data, no client information.

StrategyEvidenceTranslatePlanprogramme scoping · illustrative5research questions12candidate aims3priorities4evidence gapsPRIORITY RANKINGrelative valueAim A9Aim B7.6Aim C6.4Aim D4.8Aim E3.5ranked against agreed criteriaFROM QUESTIONS TO A PLANnarrowingOpen questions12Candidate aims8Priorities3Agreed plan1scope agreed with your teamAIM × EVIDENCE TYPEwhat is neededLit.OmicsClin.AssayAim AAim BAim CAim DAim Ewhere evidence is thinPROGRAMME FOCUSshare of effortTarget biology32%Biomarkers28%Translational22%Computational18%balanced across themesROADMAPphasesScopecompleteReviewin progressPlanplannedDecideplannedQUESTIONS AGREEDchecksObjectives definedSuccess criteria setConstraints notedData sources listed420records screened38studies included5evidence themes3gaps foundEVIDENCE SCREENING420 → 38Records screened420Relevant120Eligible64Included38inclusion criteria appliedEVIDENCE BY THEMEstudiesTheme 114Theme 210Theme 37Theme 45Theme 52where the evidence sitsEFFECT ACROSS STUDIES95% CIStudy 1Study 2Study 3Study 4Pooledeffect size (95% CI)direction agrees, precision variesTHEME × STUDY TYPEcoverageRCTCohortOmicsIn vitroscoreT188%T274%T363%T451%T538%strongest where several types agreeSTUDY QUALITYscorequality scorequality weighed, not hiddenLIMITATIONS NOTEDchecksSmall samples flaggedHeterogeneity reviewedPublication bias consideredMissing data stated24candidate markers6shortlisted3assay routes2endpointsCANDIDATE DISCOVERYdifferentiallog₂ fold change−log₁₀ pcandidates pass effect and significanceSHORTLISTING24 → 6Candidates24Robust14Plausible9Shortlist6stepwise, with reasons recordedMARKER × PLATFORMfeasibilityArrayPCRImmunoMSM1M2M3M4M5routes to a practical assayDISCRIMINATIONROCShortlist0.84Best single0.721 − specificityshortlist beats any single markerPATHWAY CONTEXTnetworkTargetPathwayMarkerOutcomemarkers tied to biologyMARKER RANKINGtop 6Marker 19.1Marker 28Marker 37.1Marker 45.8Marker 54.9Marker 63.8evidence-weighted score11weeks4work packages6data needs1planWORK PLANpackagesDesigncompleteDatain progressAnalysisplannedReviewplannedReportplannedEFFORT BY PACKAGEweeksAnalysis5Data3Review2Design1eleven weeks in totalDATA AND COMPUTE NEEDSchecksCohort access confirmedCompute plan setMethods agreedClinical metadataRESOURCE SPLITshareScientific lead34%Analyst38%Your team28%clear ownersRISKSlikelihood × impactLowMedHighDataMethodTimelineScopetracked and mitigatedDELIVERABLEShandoverEvidence reviewRecommendationsStrategy documentImplementation planillustrative sample engagement, no client data

01

Pharmaceutical Consultancy

Strategy and evidence for pharmaceutical and biotechnology projects.

02

AI in Healthcare Implementation

Plan, introduce and evaluate AI within healthcare workflows.

03

Scientific & Bioinformatics Consultancy

Research design, methods and interpretation.

Pharmaceutical consultancy

Strategy that starts from the evidence.

Where the question is strategic as well as scientific, we help you set priorities, review the evidence, plan biomarker and target work and scope the computational research that supports it.

Pharmaceutical teams

Biotechnology companies

Translational research groups

Questions we help with

01

Which research directions deserve priority, and what evidence supports them?

02

What does the existing evidence show, and where are the gaps?

03

Which biomarkers or targets are worth taking forward, and how should they be validated?

04

What data, methods and resources does the computational plan need?

Where we can help

01

Drug Discovery Strategy

Define research priorities and evidence needs.

02

Translational Research Planning

Connect molecular research objectives with translational questions.

03

Biomarker Strategy

Plan discovery, prioritisation and validation.

04

Scientific Evidence Review

Assess available evidence and its limitations.

05

Computational Research Planning

Scope methods, data and technical requirements.

Your starting point

Research objectives, available data, current challenges and intended outcomes.

Agreed deliverables

An evidence review, recommendations, a strategy or an implementation plan.

Sample engagement

Follow a sample engagement from strategy to plan.

Click through the tabs. Illustrative sample data, no client information.

StrategyEvidenceTranslatePlanprogramme scoping · illustrative5research questions12candidate aims3priorities4evidence gapsPRIORITY RANKINGrelative valueAim A9Aim B7.6Aim C6.4Aim D4.8Aim E3.5ranked against agreed criteriaFROM QUESTIONS TO A PLANnarrowingOpen questions12Candidate aims8Priorities3Agreed plan1scope agreed with your teamAIM × EVIDENCE TYPEwhat is neededLit.OmicsClin.AssayAim AAim BAim CAim DAim Ewhere evidence is thinPROGRAMME FOCUSshare of effortTarget biology32%Biomarkers28%Translational22%Computational18%balanced across themesROADMAPphasesScopecompleteReviewin progressPlanplannedDecideplannedQUESTIONS AGREEDchecksObjectives definedSuccess criteria setConstraints notedData sources listed420records screened38studies included5evidence themes3gaps foundEVIDENCE SCREENING420 → 38Records screened420Relevant120Eligible64Included38inclusion criteria appliedEVIDENCE BY THEMEstudiesTheme 114Theme 210Theme 37Theme 45Theme 52where the evidence sitsEFFECT ACROSS STUDIES95% CIStudy 1Study 2Study 3Study 4Pooledeffect size (95% CI)direction agrees, precision variesTHEME × STUDY TYPEcoverageRCTCohortOmicsIn vitroscoreT188%T274%T363%T451%T538%strongest where several types agreeSTUDY QUALITYscorequality scorequality weighed, not hiddenLIMITATIONS NOTEDchecksSmall samples flaggedHeterogeneity reviewedPublication bias consideredMissing data stated24candidate markers6shortlisted3assay routes2endpointsCANDIDATE DISCOVERYdifferentiallog₂ fold change−log₁₀ pcandidates pass effect and significanceSHORTLISTING24 → 6Candidates24Robust14Plausible9Shortlist6stepwise, with reasons recordedMARKER × PLATFORMfeasibilityArrayPCRImmunoMSM1M2M3M4M5routes to a practical assayDISCRIMINATIONROCShortlist0.84Best single0.721 − specificityshortlist beats any single markerPATHWAY CONTEXTnetworkTargetPathwayMarkerOutcomemarkers tied to biologyMARKER RANKINGtop 6Marker 19.1Marker 28Marker 37.1Marker 45.8Marker 54.9Marker 63.8evidence-weighted score11weeks4work packages6data needs1planWORK PLANpackagesDesigncompleteDatain progressAnalysisplannedReviewplannedReportplannedEFFORT BY PACKAGEweeksAnalysis5Data3Review2Design1eleven weeks in totalDATA AND COMPUTE NEEDSchecksCohort access confirmedCompute plan setMethods agreedClinical metadataRESOURCE SPLITshareScientific lead34%Analyst38%Your team28%clear ownersRISKSlikelihood × impactLowMedHighDataMethodTimelineScopetracked and mitigatedDELIVERABLEShandoverEvidence reviewRecommendationsStrategy documentImplementation planillustrative sample engagement, no client data

How we work

From your question to a clear next step.

01

Discuss

Your question and objectives

02

Define

Data, scope and deliverables

03

Deliver

Analysis or expert guidance

04

Review

Findings and next steps

Engagement options

Choose how we work together.

Focused consultation

Guidance on a specific question

Project advisory

Support for a defined project

Ongoing support

Advice across project milestones

Start a conversation

What are you working on?

Discuss your research question and the support you need.

Discuss Your Project

Discuss Your Project